Several virus types have been studied for use as viral vectors in gene therapy, including adenovirus, lentivirus, retrovirus, and adeno-associated virus (AAV). All platforms have their own advantages over one of the others. The recent successes with AAV and lentivirus give these vectors a boost in development. In combination with the fact that they are well studied, might make them the frontrunner for some therapeutic applications. Our Technical Lead, Kai Touw, has been interviewed by BioPharm International to discuss the potential and challenges of viral vector production for gene therapy.
Link to full article.
